Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebivolol in PH associated with HFpEF
NCT02053246Phase 4Terminated
- Sponsor
- University of Florida
- Start
- Jan 2014
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of nebivolol in pulmonary hypertension (PH), sponsored by University of Florida. Primary endpoint: Changes in Pulmonary Vascular Pressure at 18 weeks. Started Jan 2014; status: terminated.
02
Drugs
nebivolol
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT02053246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02053246.